Do Anti-BP180 Levels Reflect Bullous Pemphigoid Activity?
At a Glance
Anti-BP180 levels often move with bullous pemphigoid activity, but they are not a reliable measure of severity for every person. Doctors rely mainly on new blisters, itching, healing, physical examination, and sometimes a validated skin activity score.
In this answer
3 sections
Your anti-BP180 blood test results can often provide supportive information about how active your bullous pemphigoid is, but they do not tell the whole story. In many patients, when anti-BP180 levels drop, it suggests that treatment is working and skin symptoms—like blistering and intense itching—may begin to improve [1]. Medical research shows that, on a population level, higher anti-BP180 antibody levels are often associated with greater disease activity [2].
However, this relationship is imperfect. Some people have active disease with low or negative antibody levels, while others maintain high levels even after their skin has cleared. Because of this, your doctor will never use a blood test alone to make decisions about your care. Your daily symptoms, new blisters, and overall comfort are the most important indicators of your healing.
Understanding Anti-BP180 and Anti-BP230
When diagnosing and monitoring bullous pemphigoid, dermatologists often look for two specific autoantibodies: anti-BP180 and anti-BP230. Autoantibodies are proteins created by your immune system that mistakenly target healthy tissues—in this case, proteins in the basement membrane of your skin.
- Anti-BP180: This antibody is a major target of the immune response in bullous pemphigoid. Tracking anti-BP180 levels over time can be a helpful, supplemental way to monitor disease activity in some patients [1]. If your levels are falling, your immune system’s attack on your skin may be slowing down. However, there is no universal “cutoff” number that determines your medication dose.
- Anti-BP230: While detecting anti-BP230 is helpful as one piece of the diagnostic puzzle [3], its levels do not consistently track with how active your skin flares are [2]. A change in your anti-BP230 number doesn’t reliably indicate if your skin is getting better or worse.
Note on Diagnosis: A positive blood test for either antibody does not confirm bullous pemphigoid by itself. Diagnosis requires a combination of your clinical symptoms and a skin biopsy—specifically, a test called direct immunofluorescence, which looks for antibody deposits directly in the skin.
When Numbers and Symptoms Don’t Match
While a dropping anti-BP180 level is encouraging, blood tests are just one piece of information. Laboratories often measure this using a quantitative value (such as an ELISA score), and reference ranges vary. You should not compare numbers from different laboratories, and your lab numbers might not perfectly match how you feel today:
- The Healing Process Takes Time: Your antibody levels might drop in your blood before your existing blisters fully heal. Older blisters closing up can leave discolored skin for weeks, which does not necessarily mean the disease is still active.
- Medication-Induced BP: If your bullous pemphigoid was triggered by certain medications—particularly a class of diabetes drugs called DPP-4 inhibitors (often ending in “-gliptin”)—your anti-BP180 levels might naturally be lower even during an active flare [4]. Safety Note: Never stop or change your diabetes medication without a coordinated plan from your prescribing doctor and dermatologist.
- Clinical Assessment is Key: Some dermatologists use validated visual scoring systems, such as the Bullous Pemphigoid Disease Area Index (BPDAI), to objectively measure how much of your skin is affected by blisters, redness, and healing lesions [5][6]. Your physical exam, including checking for mouth or eye involvement, remains the primary tool for assessing recovery.
What This Means for Your Treatment
Serial testing for anti-BP180 is not standard for everyone; some clinicians repeat the test only when it helps clarify your condition. Your medication dosages are guided primarily by your physical symptoms: the formation of new lesions, intensity of itch, healing of old lesions, and any medication side effects. You should never adjust your medication doses based on a laboratory number alone.
When to Contact Your Care Team:
Even if your recent lab numbers were low or falling, contact your doctor promptly if you experience:
- Rapidly spreading new blisters
- Worsening itch
- Signs of wound infection (such as fever, increased pain, or pus)
- Blisters or sores in your mouth, throat, eyes, or genitals
Common questions in this guide
Do high anti-BP180 levels mean my bullous pemphigoid is severe?
Can a falling anti-BP180 result show that treatment is working?
Does anti-BP230 measure bullous pemphigoid activity?
Can an anti-BP180 or anti-BP230 positive test diagnose bullous pemphigoid?
Can diabetes medicines affect anti-BP180 results?
Should I compare anti-BP180 numbers from different laboratories?
What should I do if I get new blisters despite a low anti-BP180 level?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How should I interpret my anti-BP180 result, including the laboratory's specific reference range?
- 2.Are you planning to repeat this blood test periodically, or will we focus primarily on my physical symptoms?
- 3.What physical signs or scoring systems, like the BPDAI, are you using to measure my skin's healing?
- 4.Could any of my current medications, such as DPP-4 inhibitor diabetes drugs, be affecting my condition or test results?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (6)
- 1
Bullous Pemphigoid Severity and Levels of Antibodies to BP180 and BP230: A Systematic Review and Meta-Analysis.
Chou PY, Yu CL, Wen CN, et al.
JAMA dermatology 2024; (160(11)):1192-1200 doi:10.1001/jamadermatol.2024.3425.
PMID: 39356527 - 2
A Cross-Sectional Study to Correlate Disease Severity in Bullous Pemphigoid Patients with Serum Levels of Autoantibodies Against BP180 and BP230.
Muhammed N, Korgaonkar S, Pradhan V, Khopkar US
Indian dermatology online journal 2021; (12(5)):696-700 doi:10.4103/idoj.IDOJ_813_20.
PMID: 34667755 - 3
A patient with bullous pemphigoid with mucosal involvement serologically positive for anti-BP230 autoantibodies only.
Taki T, Takeichi T, Kono M, et al.
The British journal of dermatology 2020; (182(1)):221-223 doi:10.1111/bjd.18343.
PMID: 31301230 - 4
Defining dipeptidyl peptidase-4 inhibitors-related bullous pemphigoid: A single-centre retrospective study.
Nieto-Benito LM, Bergón-Sendín M, Pulido-Pérez A, et al.
Experimental dermatology 2021; (30(9)):1345-1351 doi:10.1111/exd.14387.
PMID: 34028898 - 5
The Reliability, Validity and Responsiveness of Two Disease Scores (BPDAI and ABSIS) for Bullous Pemphigoid: Which One to Use?
Wijayanti A, Zhao CY, Boettiger D, et al.
Acta dermato-venereologica 2017; (97(1)):24-31 doi:10.2340/00015555-2473.
PMID: 27244117 - 6
International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid.
Masmoudi W, Vaillant M, Vassileva S, et al.
The British journal of dermatology 2021; (184(6)):1106-1112 doi:10.1111/bjd.19611.
PMID: 33067805
This page is for informational purposes only and does not constitute medical advice. Your dermatologist or care team should interpret anti-BP180 results alongside your symptoms and examination.
Get notified when new evidence is published on Bullous pemphigoid.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.